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In a recent review published in International Journal of
Otolaryngology, Fletcher and Fritzell provide a compre-
hensive and useful summary of the clinical trials assessing
eﬃcacy of pneumococcal conjugate vaccines (PCVs) against
otitis media (OM) [1]. Although the Results section of the
review is limited to clinical trial data, the Discussion section
also includes interpretation of PCV “real-life impact” data
derived from post-implementation database studies.We have
some reservations about how these data are often interpreted
that may aﬀect Fletcher and Fritzell’s overall conclusions.
These points are stated more fully in our systematic review
of PCV eﬃcacy and eﬀectiveness data published [2] around
the same time as those authors’ contribution.
Fletcher and Fritzell provide a large study, but limited
to private insurance data, in children aged <2 years in
the United States (USA) as their prime example of PCV
eﬀectiveness [3]. However, this study was, at the time of
Fletcher and Fritzell’s publication, only one of seven US
studies assessing the impact of universal mass vaccination
with a 7-valent PCV (7vCRM) on OM visit rates [3–9].
Results of the Zhou et al. study are distinct from the others
in two main ways.
(1) Zhou et al. observed a 43% decrease in OM visit
rates, whereas the other studies reported a range
from 37% decrease to 7% increase. The two large
population-based studies analyzing nationally repre-
sentative samples showed a strong central tendency:
12% decrease in <2 year olds [5] and 13% decrease in
<5 year olds [4].
(2) Of the seven studies, only Zhou et al. observed that
OM visit rates were increasing (+14%) over the three
to five years before 7vCRM introduction rather than
already decreasing (by 16–24%).
It is thus of concern that only an outlier study in its category
received such exclusive attention.
There also appears to be a slight error (page 12,
paragraph 1) in the calculation of number of annual OM
visits prevented per 100 children aged <2 years based on the
Zhou et al. data (page 255, paragraph 5, and Figure 1), which
indicate that, compared to 1997–1999, the annual OM visit
rate in 2004 had decreased by 929 visits per 1000 person-
years and that this decrease in annual rate had already been
essentially achieved by 2002. These many visits prevented
every year from 2002 to 2004 would mean a 7-8-fold higher
eﬀectiveness estimate than the 23 annual visits per 100
children calculated by Fletcher and Fritzell or based on the
cited vaccine coverage rates of 41% in 2002, 68% in 2003,
and 73% in 2004, an implausible 163 OM visits prevented
per 100 children vaccinated.
Given the already decreasing rate of OM visits generally
observed before 7vCRM introduction in USA and elsewhere,
it is important to consider pre-/post-introduction compar-
isons by assessing confounding trends over time that may
have biased the estimates, particularly if these are more
favourable to the vaccine. A Canadian study [10] adjusted for
trend over time using time-series regression, which altered
the raw decrease in OM visit rates from 25% down to
13% attributable to 7vCRM when adjusted. A rise over
time in family thresholds for consultation or in physician
thresholds for diagnosis and reporting OM in an era of
increasing use of guidelines [11] and a role for watchful
waiting cannot be ruled out as a main basis of the trends
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over time seen. However, there are also other credible risk
factors for OM known to have undergone secular changes
through the period considered such as a shift of practice
to higher antibiotic dosage (or the doubling of long-acting
macrolide use) in US children around the same time as
7vCRM introduction or decreased exposure of children to
passive smoking [2].
The authors also briefly cite one non-US impact study
[12], which reported a 38% decrease in otorrhea rates
per emergency department visit in Greece. However, this
drop is not credibly attributable to vaccination because it
occurred 1-2 years before mass pneumococcal vaccination
with 7vCRM in Greece and no further drop was observed
when mass vaccination was eventually introduced in Greece
in 2006. A large drop could not have been due to the prior,
presumably minimal, private market use. Furthermore,
the proportion of pneumococcal otorrhea episodes due to
vaccine serotypes remained high in the period following the
decrease whereas a 1–3-year decline phase for these serotypes
(from growing herd protection) would have been required
for vaccination to constitute a valid explanation of the data.
The initial decline is instead likely to be primarily accounted
for by nonvaccine factors such as sampling artefact.
We thus urge those interested in PCV real-life impact
on OM to fully consider the methodological limitations of
the studies published so far and use a more analytic and
fully representative approach to synthesizing the evidence.
We agree with Fletcher and Fritzell that 7vCRM is eﬃcacious
and moderately eﬀective in preventing OM, but we consider
it essential to avoid overstating the magnitude of eﬀect.
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